Fully enroll the HOPE-3 clinical trial
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 May 2023
- Due
- 31 Dec 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we expect to fully enroll the currently designed study by the second half of 2023.”
What we found
Evidence strength A What the grades mean
The company reported that enrollment was complete only for Cohort A of the HOPE-3 trial by early 2024, indicating the full study (Cohorts A and B) was not fully enrolled by the 2023 deadline.
-
A Capricor Therapeutics, Inc. 8-K filed 2024-02-29
“Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy” ✓ confirmed on the page
-
A Capricor Therapeutics, Inc. 10-K filed 2025-03-26
“Approximately 105 eligible study subjects are currently enrolled in the dual-cohort study (comprised of Cohorts A and B).” ✓ confirmed on the page
Market reaction: the shares moved +6.7% against the S&P 500 over the three sessions around the disclosure (28 Feb 2024 to 4 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +182 days
- Language weakened: expected → aspirational
- 2 versions
-
Version 1 · original · stated 11 May 2023
Deadline 31 Dec 2023 (“second half of 2023”) · wording expected
-
Version 2 · stated 13 May 2024
Deadline 30 Jun 2024 (“by the end of second quarter”) · target 44 patients · wording aspirational
“on track to enroll 44 U.S. based patients by the end of second quarter in HOPE-3 (Cohort B) clinical trial”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Fully
- Deliverable
- HOPE-3 trial enrollment
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “no_evidence”, so a person decides.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CAPR-002525 · Corrections policy